Antibody therapeutics are being co-developed by AbCellera and Eli lilly and Company in collaboration with National Institute of Allergy and Infectious Diseases using pandemic response platform, for the prophylaxis and treatment of COVID-2019 infections. The technology is a microfluidic platform that uses miniaturised assays to screen antibodies from individual B cells from any species, including directly from human patients. These proprietary assays can be customised to screen for specific therapeutic properties, depending on the disease target or application. Early research is underway in the Canada.
LY CoV555 [See Adis Insight drug profile 800058899] has advanced from this research programme for coronavirus neutralising antibodies by Eli Lilly and AbCellera.
In March 2020, Abcellera and Eli Lilly entered into a research and development agreement to develop antibodies for up to nine Eli Lilly-selected therapeutic targets. One of therapeutic targets is for treatment and prevention of COVID-19 infections, caused by SARS-CoV-2 coronavirus. Eli Lilly will select up to eight additional targets during the multi-year agreement. Abcellera's rapid pandemic response platform developed under the DARPA Pandemic Prevention Platform (P3) programme will be used in this collaboration along with Eli lilly's rapid development, manufacturing and distribution of therapeutic antibodies. Under the terms of agreement Abcellera and Eli lilly will together fund the initial development cost of the product, after which Eli lilly will be responsible for all further development, manufacturing and distribution. Eli lilly has paid AbCellera an up-front payment and will pay preclinical, clinical, and commercial milestones and tiered royalties on future sales.  
Key Development Milestones
In May 2020, Abcellera received fund worth of $175.6 million from the Government of Canada. The fund was allocated under Innovation, Science and Economic Development’s (ISED) Strategic Innovation Fund (SIF) to support and expand the discovery of antibodies for the prophylaxis and treatment of COVID-2019 infections, and to build technology and manufacturing infrastructure for the antibody therapies  .